-
04:33:16 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

MRK Stock News

09/29/22 3:22 PM
NYSE : MRK
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
Merck, known as MSD outside of the United States and Canada, announced today that the U.S. Court of Appeals for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals, Inc. related to sitagliptin dihydrogen phosphate, an active ingredient in JANUVIA (R), JANUMET (R) and JANUMET (R) XR. Viatris had challenged validity...
RHEA-AI
neutral
09/27/22 6:45 AM
NYSE : MRK
Merck's KEYTRUDA(R) (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Merck, known as MSD outside of the United States and Canada, today announced that KEYTRUDA, Merck' s anti-PD-1 therapy, received four new approvals from Japan' s Ministry of Health, Labor and Welfare:. "Based on compelling data from our clinical trial program, KEYTRUDA has become an important treatment option in Japan and now has 23 approved uses across 13 different...
RHEA-AI
neutral
09/22/22 6:45 AM
NYSE : MRK
LYNPARZA(R) (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
AstraZeneca and Merck, known as MSD outside of the United States and Canada, today announced that LYNPARZA has been approved in China as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in...
RHEA-AI
positive
09/20/22 6:45 AM
NYSE : MRK
clinical trial
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
Merck, known as MSD outside of the United States and Canada, announced today that the company will initiate a new Phase 3 clinical program with once-daily islatravir for the treatment of people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir. The U.S. Food and Drug...
RHEA-AI
neutral
09/16/22 7:30 AM
NYSE : MRK
Merck Receives Positive CHMP Opinion for VAXNEUVANCE(TM) (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
Merck, known as MSD outside of the United States and Canada, announced today that the European Medicines Agency' s Committee for Medicinal Products for Human Use has recommended the approval of VAXNEUVANCE(TM) for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants,...
RHEA-AI
neutral
09/12/22 8:55 AM
Nasdaq, NYSE, OTC : SGEN, MRK, ALPMY
clinical trial
Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (enfortumab vedotin-ejfv) with KEYTRUDA(R) (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
- Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab -- Data highlighted in late-breaking presentation at the European Society for Medical Oncology (ESMO) Congress 2022 -TOKYO and BOTHELL,
RHEA-AI
neutral